Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.41 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3114608 | 0.93 | DPP4 (0.44) | DPP4CRHR1CYP3A4DPP8DPP9 | |
| SCHEMBL3114685 | 0.90 | CRHR1 (0.38) | CRHR1 | |
| SCHEMBL4906797 | 0.89 | DPP4 (0.53) | DPP4CRHR1CYP3A4DPP8DPP9 | |
| SCHEMBL5187409 | 0.84 | DPP4 (0.44) | DPP4CRHR1DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL4913608 | 0.83 | DPP4 (0.43) | DPP4CRHR1DPP8DPP9 | |
| SCHEMBL3109826 | 0.82 | GRM5 (0.38) | — | |
| SCHEMBL4910547 | 0.79 | DPP4 (0.45) | DPP4CRHR1DPP8DPP9 | |
| SCHEMBL3954111 | 0.79 | DPP4 (0.39) | DPP4CRHR1CYP3A4 | |
| SCHEMBL3106224 | 0.78 | DPP4 (0.47) | DPP4CRHR1 | |
| SCHEMBL3107244 | 0.78 | PPARD (0.44) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362045-B2 | 5,6-diaryl pyridines substituted in the 2- and 3-position, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-29 | — | — | US | disclosed |
| US-20100256202-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-10-07 | — | — | US | disclosed |
| EP-2209768-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009087285-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256202-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | ALK, ROS1, CYP11B2 | DPP4 1949/4885CRHR1 2350/4885CYP3A4 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.